You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物經營交流會大幅下調2023年部分板塊營收和盈利預期
格隆匯 12-04 10:13
格隆匯12月4日丨藥明生物今日在經營交流會上稱,主要預期藥物開發(D)營收下降18%-20%,生產(M)營收下降15%-18%。藥物開發業務端收入增速低於預期,主要由於在下行週期中公司2023年目標新增120個項目顯然過於激進;生物技術融資放緩導致新增項目減少,比去年減少40個新項目意味着減少約3億美元收入。生產端收入下降主要由於今年下半年的主要意外是由於監管機構批準滯後,3個來自大藥企的重磅藥延期。此前,藥明康德在三季報中也下調了全年營收預期,從之前5-7%,調整至2-3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account